The present invention relates to a unique oncolytic virus, Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU), and to methods and pharmaceutical compositions comprising thereof for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.

Disclosed is a novel vaccine formulation for prevention against Bluetongue virus infection in domestic and wild ruminants, cattle, goats, sheep, pigs, and any other mammals for commercial use. The antigen present in the vaccine is an inactivated antigen comprising 5 different serotypes of Bluetongue virus, thereby making a pentavalent vaccine formulation against Bluetongue virus infections. Also disclosed are method of adaptation of Bluetongue virus in suspension culture upto 2000 liters industrial size bioreactors, and inactivation techniques for preparation of the given vaccine formulation with the presence of suitable adjuvants and preservatives.

The present invention relates to a unique oncolytic virus, Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU), and to methods and pharmaceutical compositions comprising thereof for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.

The invention relates to methods for producing a propagation-competent strain of a mutant Reoviridae virus, and to a propagation-competent strain of a mutant Reoviridae virus that is obtainable by a method of the invention. The invention further relates to a propagation-competent strain of a mutant Reoviridae virus, comprising a deletion of a genetic region that is relevant for propagation of the virus, and to a vaccine, comprising a propagation-competent strain of a mutant Reoviridae virus.